🎯Working on difficult-to-drug targets can feel like walking a tight rope through chemical space.
At Recursion, we’re using AI agents to work alongside our scientists, and help us navigate that tight rope with precise steps.
We’re making 97 billion predictions across 5.5
Decoding biology to radically improve lives. The industrial revolution of drug discovery is here.
- 📣 In a new story in @GENbio, @AlexWestchester spoke with Recursion VP of Neuroscience Chris Winrow about the delivery of the first neuroscience target from our partnership with Genentech, which has now been validated and is advancing in a joint early-discovery program.
- 🚀 How we unlocked the first neuroscience target for the Recursion and Genentech collaboration. The collaboration began with a mission to unlock new targets in one of medicine's most challenging therapeutic areas: neuroscience. Today, that work has reached an important
- Join us on Wednesday, August 5 at 8am ET / 6am MT / 1pm BST for our Q2 2026 Earnings Call where we'll provide business updates and report our second quarter 2026 financial results. x.com/i/broadcasts/1… Questions may be submitted at: forms.gle/UGRGWTckLVJAq1…
- Today, Recursion reports its second quarter financial results and business updates, showing demonstrated progress across partnerships, clinical programs, and financial goals. 🚀 Highlights include: ▪️Genentech advanced the collaboration's first neuroscience target into a joint

